Achmea Investment Management B.V. Boosts Stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Achmea Investment Management B.V. grew its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 5.0% during the second quarter, HoldingsChannel reports. The fund owned 23,205 shares of the company’s stock after acquiring an additional 1,111 shares during the quarter. Achmea Investment Management B.V.’s holdings in IDEXX Laboratories were worth $11,306,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Jupiter Asset Management Ltd. grew its stake in IDEXX Laboratories by 61.9% in the second quarter. Jupiter Asset Management Ltd. now owns 166,145 shares of the company’s stock valued at $80,946,000 after purchasing an additional 63,493 shares during the last quarter. American Century Companies Inc. boosted its holdings in shares of IDEXX Laboratories by 46.0% in the 2nd quarter. American Century Companies Inc. now owns 562,764 shares of the company’s stock valued at $274,179,000 after buying an additional 177,226 shares in the last quarter. Trifecta Capital Advisors LLC grew its position in shares of IDEXX Laboratories by 13,200.0% in the 2nd quarter. Trifecta Capital Advisors LLC now owns 665 shares of the company’s stock worth $324,000 after buying an additional 660 shares during the last quarter. HHM Wealth Advisors LLC raised its stake in shares of IDEXX Laboratories by 135.8% during the 2nd quarter. HHM Wealth Advisors LLC now owns 191 shares of the company’s stock worth $93,000 after acquiring an additional 110 shares in the last quarter. Finally, Angeles Wealth Management LLC lifted its position in IDEXX Laboratories by 4.1% during the second quarter. Angeles Wealth Management LLC now owns 1,053 shares of the company’s stock valued at $513,000 after acquiring an additional 41 shares during the last quarter. 87.84% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on IDXX shares. Stifel Nicolaus cut their price target on shares of IDEXX Laboratories from $520.00 to $510.00 and set a “hold” rating on the stock in a report on Monday, June 24th. BTIG Research initiated coverage on IDEXX Laboratories in a research note on Thursday, July 25th. They set a “buy” rating and a $580.00 target price on the stock. StockNews.com cut IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Wednesday, July 10th. Finally, Piper Sandler dropped their price target on IDEXX Laboratories from $600.00 to $520.00 and set a “neutral” rating on the stock in a research note on Wednesday, August 14th. Three research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $582.25.

IDEXX Laboratories Stock Up 1.4 %

IDEXX Laboratories stock opened at $497.04 on Friday. IDEXX Laboratories, Inc. has a fifty-two week low of $372.50 and a fifty-two week high of $583.39. The company has a market cap of $41.05 billion, a PE ratio of 48.12, a PEG ratio of 4.02 and a beta of 1.33. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.03 and a current ratio of 1.37. The business’s 50-day simple moving average is $480.89 and its two-hundred day simple moving average is $502.21.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings results on Tuesday, August 6th. The company reported $2.44 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.88 by ($0.44). IDEXX Laboratories had a return on equity of 57.03% and a net margin of 22.34%. The business had revenue of $1 billion for the quarter, compared to analysts’ expectations of $1.01 billion. During the same period in the prior year, the business posted $2.67 earnings per share. The business’s quarterly revenue was up 6.4% compared to the same quarter last year. Equities analysts anticipate that IDEXX Laboratories, Inc. will post 10.45 EPS for the current year.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.